Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pilulka Lekarny AS's revenue for the
six
months ended in Dec. 2025 was Kč0 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was Kč1,304 Mil.
Pilulka Lekarny AS's Revenue per Share for the
six
months ended in Dec. 2025 was Kč0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was Kč481.80.
Warning Sign:
Pilulka Lekarny AS revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Pilulka Lekarny AS was -32.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -30.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Pilulka Lekarny AS's highest 3-Year average Revenue per Share Growth Rate was 3.80% per year. The lowest was -30.40% per year. And the median was -20.00% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Pilulka Lekarny AS Revenue Related Terms
Pilulka Lekarny AS Revenue Historical Data
* Premium members only.
The historical data trend for Pilulka Lekarny AS's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Pilulka Lekarny AS's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pilulka Lekarny AS Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pilulka Lekarny AS's Revenue distribution charts can be found below:
* The bar in red indicates where Pilulka Lekarny AS's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Kč1,304 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pilulka Lekarny AS (XPRA:PINK) has a Revenue of Kč1,304 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Pilulka Lekarny AS and its competitors.
Is Pilulka Lekarny AS's Revenue too high?
Pilulka Lekarny AS's current Revenue is Kč1,304 Mil. Overall, Pilulka Lekarny AS has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's Revenue compare to competitors?
Pilulka Lekarny AS's Revenue of Kč1,304 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Pilulka Lekarny AS and its competitors. Pilulka Lekarny AS's current Revenue is Kč1,304 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč109.75, compared to a current price of Kč117.00 — trading 6.6% above its estimated fair value. The current Revenue is Kč1,304 Mil. Pilulka Lekarny AS's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current Revenue is Kč1,304 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?
Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be overvalued.
The current stock price of Kč117.00 is trading 6.6% above its estimated GF Value™ of Kč109.75.
GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.
Key valuation signals for XPRA:PINK:
Revenue: Kč1,304 Mil
GF Value™: Kč109.75 vs. price of Kč117.00 (6.6% above fair value)
No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
52GF Score
Get the complete analysis for XPRA:PINK
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPRA:PINK has been successfully added to your 
